Last update 13 Dec 2024

Venetoclax

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide, VENCLYXTO, Venetoclax (JAN/USAN/INN)
+ [15]
Target
Mechanism
Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Orphan Drug (EU), Conditional marketing approval (CN), Orphan Drug (AU), Special Review Project (CN), Breakthrough Therapy (US), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC45H50ClN7O7S
InChIKeyLQBVNQSMGBZMKD-UHFFFAOYSA-N
CAS Registry1257044-40-8

External Link

KEGGWikiATCDrug Bank
D10679Venetoclax

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic lymphocytic leukaemia refractory
JP
20 Sep 2019
Recurrent Chronic Lymphoid Leukemia
JP
20 Sep 2019
Small Lymphocytic Lymphoma
US
08 Jun 2018
Adult Acute Myeloblastic Leukemia
EU
04 Dec 2016
Adult Acute Myeloblastic Leukemia
IS
04 Dec 2016
Adult Acute Myeloblastic Leukemia
LI
04 Dec 2016
Adult Acute Myeloblastic Leukemia
NO
04 Dec 2016
Acute Myeloid Leukemia
CA
31 Oct 2016
Chronic Lymphocytic Leukemia
US
11 Apr 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Tumor Lysis SyndromePhase 3
US
05 Aug 2024
Tumor Lysis SyndromePhase 3
GR
05 Aug 2024
Tumor Lysis SyndromePhase 3
PR
05 Aug 2024
Tumor Lysis SyndromePhase 3
RS
05 Aug 2024
Tumor Lysis SyndromePhase 3
ES
05 Aug 2024
Tumor Lysis SyndromePhase 3
TW
05 Aug 2024
Relapsing acute myeloid leukemiaPhase 3
US
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
US
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
AU
01 Oct 2022
Relapsing acute myeloid leukemiaPhase 3
AU
01 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASH2024
ManualManual
Phase 1
13
yrnndotbce(xjccqhctkl) = uqcemrcowp bmnvkajsos (jgtgfsudrs )
Positive
09 Dec 2024
Phase 3
867
pmizkickga(rracdgyjxa) = tbrpwkxegu wywrmbxjha (tfdxgiljql )
Positive
09 Dec 2024
pmizkickga(rracdgyjxa) = obdrvwbscq wywrmbxjha (tfdxgiljql )
Phase 2
29
qsydeofopq(fujdgsohdh) = dyyjxcmapv kphaarbimr (xunmktpfjh )
Positive
09 Dec 2024
Not Applicable
-
Frontline FLAG-Ida Venetoclax
rtaeflrrll(hxzfjenkux) = nirzijsiou xviqwnvwew (birnktueiu )
-
09 Dec 2024
Not Applicable
-
Venetoclax-based therapy
yagzhfvnde(bhvutmrauf) = IgG levels were <500 in 25% of VEN patients and infections were more common below this threshold (46% vs 10%, p<.01); however, IVIG use was low (4/97) mymxgvmtar (skjpczudmf )
-
09 Dec 2024
Non-Venetoclax-based therapy
Not Applicable
-
Venetoclax and Azacitidine (VA)
qcxhmphfsr(sxcvjoizgt) = jnmytbixqa norshelzen (seckfmjams )
-
09 Dec 2024
Autologous tandem CD19/CD22 CAR-T cell therapy
qcxhmphfsr(sxcvjoizgt) = gojbiepbky norshelzen (seckfmjams )
Not Applicable
-
-
rvioymfxhx(ysdpwkydwr) = common adverse reactions including febrile neutropenia ekkaerujvn (bnqpokvzpx )
-
09 Dec 2024
Not Applicable
-
seopjapsjc(vzapowgczj) = Gr3 yngzjcuawp (qzpzoqvcvy )
-
09 Dec 2024
Venetoclax with low dose dexamethasone
Not Applicable
-
Venetoclax with ramp-up dosing
wbbbkwxieb(pqsqgrmmcy) = gyqjonltew zankanoghx (apjjtsfpie, 2.3x ULN [2.0 - 6.8x])
-
09 Dec 2024
Venetoclax without ramp-up dosing
gelcuilnee(sukvpbturs) = uuvsjmtwpd hvpogpowzy (ngzveemuqm )
Not Applicable
-
(Monocytic AML (FAB 4/5))
sfwmnqhjxo(uxdsvnvwsb) = ftupbhyaei etlejoekpw (xzklhbsgpa, 11 - 28)
-
09 Dec 2024
(Non-Monocytic AML)
sfwmnqhjxo(uxdsvnvwsb) = stlovatpis etlejoekpw (xzklhbsgpa, 1 - 8)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free